The prevalence of bronchogenic lung cancer (BLC) in patients with idiopathic pneumonic fibrosis (IPF)

G. S. Vlachogeorgos, I. K. Michailidou, A. N. Xyfteri, K. S. Malagari, N. A. Karagiannidis, E. G. Kastanakis, E. T. Passalidou, V. S. Polychronopoulos (Athens, Greece)

Source: Annual Congress 2003 - Lung cancer: clinical presentation and prognostic factors
Session: Lung cancer: clinical presentation and prognostic factors
Session type: Thematic Poster Session
Number: 1649
Disease area: Interstitial lung diseases, Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. S. Vlachogeorgos, I. K. Michailidou, A. N. Xyfteri, K. S. Malagari, N. A. Karagiannidis, E. G. Kastanakis, E. T. Passalidou, V. S. Polychronopoulos (Athens, Greece). The prevalence of bronchogenic lung cancer (BLC) in patients with idiopathic pneumonic fibrosis (IPF). Eur Respir J 2003; 22: Suppl. 45, 1649

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases
Year: 2012

Telomerase expression in idiopathic pulmonary fibrosis (IPF) and non small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012

UIP-like or NSIP pattern in interstitial lung disease patients (ILD), following by ‘connective tissue disease ‘(CTD)
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012

Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013


Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013

A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020


Interstitial fibrosis with a nodule
Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session
Year: 2007

The prevalence of neoplastic transformation in idiopathic pulmonary fibrosis (IPF) lungs. A report from a transplanted IPF population
Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis
Year: 2011


Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2008; 32: 170-174
Year: 2008



Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 409s
Year: 2001

Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018



Tumour infiltrating lymphocytes and tumour associated macrophages in chronic obstructive pulmonary disease (COPD) patients with non-small cell lung cancer (NSCLC) and in patients with NSCLC
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005

Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010

Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016


Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD)
Source: Eur Respir J 2004; 24: Suppl. 48, 533s
Year: 2004

Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006


Overall survival is significantly higher in sarcoidosis than in IPF patients after lung transplantation
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013


Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005